Anti-CD138-interferon alpha2 fusion protein(Qwixel Therapeutics)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD138-interferon alpha2 fusion protein(Qwixel Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > ImmunoglobulinBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionCell proliferation inhibitorsApoptosis stimulants

TargetsNot applicable

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California At Los Angeles

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California At Los Angeles

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A